7,568.92

+27.52

+0.36%

51,786.72

-197.26

-0.38%

25,372.01

+207.65

+0.83%

2,812.45

+6.57

+0.23%

4.9520

+0.0580

+1.19%

20.83

-0.32

-1.51%

3,937.60

-32.00

-0.81%

77,927.44

+1,224.69

+1.60%

Crude Oil Dec 26

96.76

+0.30

+0.31%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqCM - Nasdaq Real Time Price USD

Veru Inc. (VERU)

2.1600 0.0000 (0.00%)

At close: 4:00:01 PM EST

2.0887 -0.0713 (-3.30%)

After hours: 4:33:43 PM EST

Loading Chart for VERU

Chart Range Bar

Interval:

In partnership with ChartIQ

Veru (VERU) Q3 2026 Earnings Call Transcript

Veru (VERU) Q3 2026 Earnings Call Transcript

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Veru And 2 Other Intriguing Penny Stocks To Watch

Veru And 2 Other Intriguing Penny Stocks To Watch

Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)

Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clinical Trial Results Amid ...

Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clinical Trial Results Amid ...

Mobilize your Website

View Site in Mobile | Classic

Share by: